Share Price | 4D Molecular Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is 4D Molecular Therapeutics, Inc.?

Market Cap: As of Jun 18, 4D Molecular Therapeutics, Inc. has a market capitalization of 192.25 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.02 million and a net profit of -176.43 million.Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds amounting to 510.61 million and total assets of 560.38 million.

Q: What does 4D Molecular Therapeutics, Inc. do?

Overview:4D Molecular Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot:Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -48 Million (Quarterly Results - Mar 2025) Market-cap: USD 192.25 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.67 Return on Equity: -37.57% Price to Book: 0.41Contact Details:Details: No Company Details Available Registrar Address: Not available.

Q: Is 4D Molecular Therapeutics, Inc. overvalued or undervalued?

As of 28 February 2025, the valuation grade for 4D Molecular Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently assessed as overvalued, given its negative financial metrics and lack of profitability. Key ratios include a Price to Book Value of 0.43, an EV to EBIT of 0.56, and an EV to EBITDA of 0.58, all of which suggest a lack of financial health.In comparison to its peers, 4D Molecular Therapeutics, Inc. shows a stark contrast with Enliven Therapeutics, Inc. at an EV to EBITDA of -11.1774 and Avid Bioservices, Inc. at -118.0909, both indicating severe valuation challenges within the industry. The company's recent stock performance has been notably poor, with a year-to-date return of -32.32%, significantly underperforming the S&P 500's 2.44% return. This further reinforces the conclusion that the company is overvalued in its current state.

Q: Is 4D Molecular Therapeutics, Inc. technically bullish or bearish?

As of 25 August 2025, the technical trend for 4D Molecular Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The RSI shows a bullish signal on the monthly timeframe, although there is no signal on the weekly. The daily moving averages are bullish, supporting the overall positive stance. However, the Bollinger Bands indicate a mildly bearish trend on the monthly, and the KST is bearish on that same timeframe. The Dow Theory reflects a mildly bullish stance on the weekly but shows no trend on the monthly. The On-Balance Volume is mildly bearish on the weekly and shows no trend on the monthly.In terms of multi-period returns, the stock has outperformed the S&P 500 year-to-date with a return of 27.47% compared to 12.22%, but it has significantly underperformed over the past year and three years, with returns of -57.79% and -19.77%, respectively. Overall, the current technical stance is mildly bullish, driven primarily by the bullish signals in MACD and moving averages.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

778.8 k

Shareholding (Sep 2025)

FII

19.64%

Held by 93 FIIs

DII

48.17%

Held by 31 DIIs

Promoter

6.92%

How big is 4D Molecular Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, 4D Molecular Therapeutics, Inc. has a market capitalization of 192.25 million, with net sales of 0.02 million and a net profit of -176.43 million over the latest four quarters. The company has shareholder's funds of 510.61 million and total assets of 560.38 million as of Dec 24.

View full answer

What does 4D Molecular Therapeutics, Inc. do?

22-Jun-2025

4D Molecular Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 and a net loss of $48 million as of March 2025. The company has a market cap of $192.25 million and key metrics indicate it is currently loss-making with no dividend yield.

View full answer

Is 4D Molecular Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of February 28, 2025, 4D Molecular Therapeutics, Inc. is assessed as overvalued and has deteriorated to a "does not qualify" valuation grade due to negative financial metrics, poor stock performance, and significant contrasts with peers.

View full answer

Is 4D Molecular Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, 4D Molecular Therapeutics, Inc. shows a mildly bullish trend supported by positive MACD and moving averages, despite mixed signals from Bollinger Bands and On-Balance Volume, while year-to-date performance outpaces the S&P 500 at 27.47%.

View full answer

Compare 4D Molecular Therapeutics, Inc. with Similar Stocks

HilleVax, Inc.Alector, Inc.Allogene Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 439 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.81

Return on Equity

-56.70%

Price to Book

1.19

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-55 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-17.67%

6 Months

56.89%

1 Year

37.88%

2 Years

-72.93%

3 Years

-58.57%

4 Years

-44.98%

5 Years

-82.02%

4D Molecular Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-79.38%

EBIT Growth (5y)

-221.69%

EBIT to Interest (avg)

-108.77

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.67

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.43

EV to EBIT

0.56

EV to EBITDA

0.58

EV to Capital Employed

-0.74

EV to Sales

-114.25

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-37.57%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

Bullish

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 46 Schemes (25.27%)

Foreign Institutions

Held by 93 Foreign Institutions (19.64%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -13.96% vs 3.42% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-57.60",
          "val2": "-51.90",
          "chgp": "-10.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-54.70",
          "val2": "-48.00",
          "chgp": "-13.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,963,733.30%",
          "val2": "-3,830,071.40%",
          "chgp": "-13,366.19%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 567.74% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -59.62% vs 6.23% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "20.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-181.10",
          "val2": "-107.10",
          "chgp": "-69.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-160.90",
          "val2": "-100.80",
          "chgp": "-59.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,076,783.80%",
          "val2": "-5,446.50%",
          "chgp": "-5,07,133.73%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-57.60

-51.90

-10.98%

Interest

0.00

Exceptional Items

-0.00

0.10

-100.00%

Consolidate Net Profit

-54.70

-48.00

-13.96%

Operating Profit Margin (Excl OI)

-3,963,733.30%

-3,830,071.40%

-13,366.19%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -13.96% vs 3.42% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

20.70

-100.00%

Operating Profit (PBDIT) excl Other Income

-181.10

-107.10

-69.09%

Interest

0.00

Exceptional Items

-0.00

-0.20

100.00%

Consolidate Net Profit

-160.90

-100.80

-59.62%

Operating Profit Margin (Excl OI)

-5,076,783.80%

-5,446.50%

-5,07,133.73%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 567.74% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -59.62% vs 6.23% in Dec 2023

All Annual Results

Company CV

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

4D Molecular Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is 4D Molecular Therapeutics, Inc.?

Watch in Real-Time

What does 4D Molecular Therapeutics, Inc. do?

Is 4D Molecular Therapeutics, Inc. overvalued or undervalued?

Is 4D Molecular Therapeutics, Inc. technically bullish or bearish?

Compare 4D Molecular Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About 4D Molecular Therapeutics, Inc.

Company Coordinates